During the GvHD Hub Steering Committee meeting in November 2022, key opinion leaders met to discuss what supportive care should look like for patients with chronic graft-versus-host disease (GvHD). The recorded discussion was chaired by Profess

How would you treat aGvHD in your clinic (an EU perspective)?

May 11th, 2022 5m 33s

During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Gérard Socié, Hôpital Saint-Louis, Paris, FR. We asked, How would you treat acute GvHD (aGvHD) in your clini

What should supportive care look like for patients with GvHD? What role does physical activity play in these patients?

Apr 13th, 2022 15m 28s

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Zinaida Perić, University of Zagreb, Zagreb, HR, and Bipin Savani, Vanderbilt University Medical Center, Na

How do we stratify risk in patients with GvHD?

Apr 11th, 2022 3m 52s

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Daniel Weisdorf, University of Minnesota, Minneapolis, US. We asked, How do we stratify risk in patients wi

What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

Dec 23rd, 2021 13m 57s

During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to steering committee member Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH

How can patient-reported QoL change our view on unmet needs in GvHD?

Apr 7th, 2021 16m 56s

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Nada Hamad, St Vincent's Hospital Sydney, Sydney, AU, and Silvy Lachance, Hôpital Maisonneuve-Rosemont, Montreal, CA. We a

How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease

Jun 29th, 2020 24m 35s

During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the GvHD Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvan

Rate